Medigus Board of Directors Decides to Promote a $2 Million Buyback Program
Medigus Ltd. (Nasdaq: MDGS) has announced a $2 million buyback program for its ADRs, pending court approval. The initiative aims to enhance shareholder value and will be formally approved alongside its financial statements for the six months ending June 30, 2021. The company is also expected to seek a financial advisor's opinion to facilitate this process. The effectiveness of this program hinges on legal validation, reflecting Medigus' commitment to its investors while acknowledging potential risks associated with the buyback.
- Authorization of a $2 million buyback program aimed at enhancing shareholder value.
- The buyback is expected to be approved alongside financial statements, indicating financial management oversight.
- The buyback program is contingent on court approval, introducing uncertainty regarding its implementation.
- Potential risks associated with the forward-looking statements could affect the anticipated benefits of the buyback.
OMER, Israel, July 26, 2021 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced its board of directors authorized the company to take actions to promote a
About Medigus
Medigus is traded on the Nasdaq Capital Market. To learn more about the company’s advanced technology, please visit http://www.medigus.com/investor-relations
Cautionary Note Regarding Forward Looking Statements
This press release may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions and expectations of Medigus’ management and its knowledge of the relevant market. The company has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. For example, Medigus uses forward looking statements when describing the contemplated buyback program as there is no assurance that any of the conditions required by law for the effectiveness of the program will be satisfied and accordingly whether the buyback program will be initiated and its timing. These forward-looking statements represent Medigus’ expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. By their nature, Forward-Looking Statements involve known and unknown risks, uncertainties and other factors which may cause future results of the Medigus’ activity to differ significantly from the content and implications of such statements. Other risk factors affecting Medigus are discussed in detail in the Medigus’ filings with the Securities and Exchange Commission. Forward-Looking Statements are pertinent only as of the date on which they are made, and Medigus undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, future developments or otherwise. Neither Medigus nor its shareholders, officers and employees, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Medigus’ securities. Nothing in this press release should be deemed to be medical or other advice of any kind
FAQ
What is the purpose of Medigus's $2 million buyback program?
When will Medigus's buyback program be approved?
What are the conditions for the effectiveness of the buyback program?
What risks are associated with Medigus's buyback program?
